ArticleThe oncologist2025
Central nervous system involvement-positive disease in consolidation/maintenance stage is a poor prognostic factor in pediatric T-cell acute lymphoblastic leukemia: a Chinese single-center report.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LTF promotes central nervous system leukemia progression via neutrophil serine proteases.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe incidence of central nervous system (CNS) leukemia is approximately 5%-10% in pediatric T-cell acute lymphoblastic leukemia (T-ALL), typically conferring a poor prognosis. MATERIALS AND
methodsWe further investigated the relationship between prognosis and CNS status at different treatment stages, retrospectively examining 185 patients with pediatric T-ALL of 2131 consecutive patients with ALL seen between April 2008 and October 2020.
resultsPatients with CNS involvement-positive (CNSI+) disease during induction had lower initial platelet counts (P = .021), a higher proportion of ETP-ALL (P = .031), hepatomegaly (P = .034), and splenomegaly (P = .030), but a lower recurrence rate (P = .004) than those of patients with CNSI+ disease occurring in the consolidation/maintenance stages. Children with CNSI+ disease in the consolidation/maintenance stages by univariate/multivariate analyses had a significantly lower 10-year overall survival (OS) (46.2 ± 10.8%, 67.5 ± 9.5%, and 80.7 ± 3.4%, P = .003), event-free survival (EFS; 20.8 ± 8.3%, 48.0 ± 10.0%, and 77.4 ± 3.6%, P < .001), and a significantly higher cumulative recurrence rate (CRR) (76.8 ± 9.1%, 48.6 ± 10.1%, and 17.3 ± 3.3%, P < .001) than those of patients with CNSI+ disease in induction and those who were CNSI- (P values all <.05). PHF6, RELN, TP53, and IKZF1 mutations were more common in patients with CNSI+ observed during the consolidation/maintenance stages (P values all <.05), which may indicate a role in pathogenesis.
conclusionCNSI+ disease, especially in the consolidation/maintenance stage, was an independent poor prognostic factor in pediatric T-ALL. HSCT partially improved outcomes of children with T-ALL. Individualized treatment strategies containing a combination of immunotherapy and targeted therapy in addition to chemotherapy may improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.